Pre-IPO Investing

Showing 468 articles
Business

Oxford Lane Capital Cuts Payout Amid Market Turbulence, NAV Takes a Hit

Oxford Lane Capital (OXLC) reported a challenging third fiscal quarter, marked by a significant drop in net asset value and investment income, prompting management to reduce its monthly distribution. The firm cited volatile conditions in the CLO and leveraged loan markets as key headwinds, while outlining a strategy to preserve capital for opportunistic investments.

Business

Quarterhill's Five-Year Plunge: A 66% Loss Tests Investor Patience

Quarterhill Inc. (TSE:QTRH) shareholders have endured a punishing five-year period, with the stock's value plummeting nearly 70%. Despite modest revenue growth, the market's verdict has been harsh, raising questions about the company's path to profitability and the perils of long-term bets in turbulent sectors.

Business

Workday's Steep Slide: A Value Bet or Value Trap for Investors?

As the S&P 500 notches another year of robust gains, the concentrated nature of the rally has left some high-flying tech names like Workday in the dust. Hotchkis & Wiley's latest investor letter reveals the HR software giant was a significant drag on its value fund in Q4 2025, with shares down over 33% in a year. Against a backdrop of stretched market valuations, we examine whether this sell-off presents a compelling entry point or signals deeper troubles.

Business

Carnival Stock: A Deep Value Play After Debt Pivot and Travel Rebound?

Carnival Corporation's shares have surged over three years, yet a detailed financial analysis suggests the cruise giant may still be trading at a significant discount. As the industry navigates post-pandemic recovery and debt reduction, investors are weighing if the current price reflects underlying value or lingering risks.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Nvidia Aided China's DeepSeek In Advancing Powerful AI Models Later Linked To Military Use, House Committee Chair Alleges: Report

A U.S. lawmaker has alleged that Nvidia Corp (NASDAQ:NVDA) provided technical assistance to Chinese AI startup DeepSeek. Nvidia Technical Support Allegedly Boosted DeepSeek's Efficiency Nvidia helped DeepSeek improve the efficiency of its artificial intelligence models, according to a letter sent to the U.S. Commerce Department by Rep. John Moolenaar (R-Mich.), chair of the House Select Committee on China. The letter, seen by Reuters on Wednesday, says documents obtained by the committee show th

Business

SoFi Profits Surge as Fee-Based Boom Shields Fintech from Rate Volatility

SoFi Technologies posts a sharp rise in quarterly profit, driven by record loan demand and a 78% revenue surge in its fee-generating financial services arm. The performance highlights a strategic shift as consumers flock to digital lenders for debt consolidation, while potential regulatory headwinds loom for the credit card industry.